Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?

التفاصيل البيبلوغرافية
العنوان: Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?
المؤلفون: Julie Omolola Okiro, Abuelmagd Abdalla, Catherine Mc Hugh
المصدر: BMJ Case Reports. :bcr-2017
بيانات النشر: BMJ, 2017.
سنة النشر: 2017
مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_specialty, endocrine system diseases, Diabetic ketoacidosis, Recombinant Fusion Proteins, medicine.medical_treatment, Glucagon-Like Peptides, 030209 endocrinology & metabolism, Type 2 diabetes, Gastroenterology, Article, Glucagon-Like Peptide-1 Receptor, Diagnosis, Differential, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, Aged, business.industry, General Medicine, medicine.disease, Immunoglobulin Fc Fragments, Discontinuation, 030104 developmental biology, Endocrinology, Diabetes Mellitus, Type 2, Hyperglycemia, Lactic acidosis, Vomiting, Female, Ketosis, medicine.symptom, business
الوصف: We report two patients with chronic hyperglycaemia secondary to type 2 diabetes who developed severe vomiting on d. The first patient was diagnosed with a mixed picture of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS) and the second, with DKA. They were on insulin therapy which was discontinued on commencing d because of inefficacy and weight gain. The HHS patient developed dehydration secondary to vomiting and had lactic acidosis but no other precipitant could be found in either case. It appears that the abrupt insulin discontinuation coupled with vomiting and dehydration led to the metabolic derangements. Subsequent C-peptide levels were found to be low in both patients. In view of the predisposition of patients with chronic hyperglycaemia to glucagon-like peptide 1 receptor (GLP-1R) downregulation and the lag time to optimal efficacy of GLP-1R agonists, we propose that patients should have C-peptide levels measured to determine the risk of ketosis and whether insulin should be continued with dose adjustments when starting a GLP-1R agonist.
تدمد: 1757-790X
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d496bdb833d908000711afea7f0dc2Test
https://doi.org/10.1136/bcr-2017-220437Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....96d496bdb833d908000711afea7f0dc2
قاعدة البيانات: OpenAIRE